INTRODUCTION
The kappa opioid receptor (KOR) is a seven transmembrane G protein-coupled receptor (GPCR) (1) .
The cognate neuropeptides for KOR are endogenous opioids, including the dynorphin peptides. Dynorphins and KOR are widely expressed throughout the central nervous system (2) (3) (4) . In a canonical sense, KOR activation is defined by agonist-induced coupling of the Gα subunit of the heterotrimeric G proteins in the pertussis toxin-sensitive G i/o family (5), subsequent inhibition of adenylyl cyclase (6), activation of inward-rectifying potassium channels (7), and blockade of calcium channels (8).
There is considerable evidence that selective KOR agonists produce antinociception in animal models (9-12) and mice lacking KOR expression are no longer responsive to the antinociceptive effects of a selective KOR agonist U50,488 (13) . The G protein-mediated signaling events are believed to contribute to the analgesic properties of KOR agonists (14, 15) . Unlike MOR agonists, KOR agonists do not cause physical dependence nor do they produce respiratory failure; thus, they are attractive as potent analgesics (16) . However, KOR activation has also been implicated in producing an array of undesirable side effects including dysphoria (17, 18) , sedation (10), diuresis (11), hallucination (19) , and depression (20) . These adverse effects limit the therapeutic potential of KOR agonists as analgesics.
It is becoming widely evident that activation of GPCRs by chemically distinct agonists can promote receptor coupling to distinct pathways in different tissues (21) (22) (23) . The KOR also has the potential to signal through multiple downstream signaling cascades and there is increasing evidence that signaling to alternate cascades may promote side effects associated with KOR activation. In addition to G protein coupling, another proximal event following GPCR activation is the agonist-promoted recruitment of βarrestins. As regulatory and scaffolding proteins, βarrestins can lead to desensitization of the receptor by impeding further G protein coupling; in some cases, βarrestins facilitate the assembly of protein scaffolds, thereby acting as signal transducers (24) (25) (26) . For example, βarrestin2 recruitment has been shown to promote recruitment and activation of MAP kinases, including ERK1/2 (27,28) and p38 (29) . Interestingly, studies in AtT-20 cells and mouse striatal neurons suggest that the KOR may signal via a GPCR kinase 3 (GRK3)-and a βarrestin2-dependent mechanism to activate the stress MAP kinase p38, and that this signaling cascade may mediate the dysphoric effects of KOR agonists (29,30). Moreover, KOR activation has been shown to lead to ERK1/2 phosphorylation in both neurons and astrocytes through both G protein and βarrestin-dependent mechanisms (28,29,31,32).
Endogenously elevated dynorphin levels produced by repeated swim stress tests lead to KOR-dependent ERK1/2 phosphorylation in mouse brain that was not dependent on GRK3 expression (33). Therefore ERK activation may be a useful indicator of both βarrestin-dependent and G protein-dependent signaling states downstream of KOR (34).
Since G protein-mediated signaling is implicated in KOR-induced antinociception and βarrestin2-mediated signaling has been implicated in the aversive and dysphoric properties of KOR agonists, the development of G protein biased agonists may provide a means to optimally tune KOR therapeutics. In two different screening campaigns, we discovered two new classes of KOR agonists, triazole probe 1 and isoquinolinone probe 2 ( Figure 1 ).
The triazole scaffold was 3 indentified under the auspices of the Molecular Libraries Probe Production Centers Network (MLPCN) via a high-throughput screening (HTS) campaign. In this work, which was done in collaboration with colleagues at Sanford-Burnham Research Institute and Duke University, the NIH Small Molecule Repository was screened to identify KOR ligands based on activation of βarrestin2 recruitment (35,36). The isoquinolinone scaffold arose from a 72-member library prepared by a tandem Diels-Alder-acylation reaction that was screened for binding at potential GPCR targets by the NIMH Psychoactive Drug Screening Program (37, 38) . The lead isoquinolinone was reported as a KOR agonist showing selectivity and high binding affinity for KOR over MOR, DOR, and other screened GPCRs (37, 38) ; moreover, the triazole lead also displayed high selectivity for KOR over MOR and DOR ( Figure 1 ) (35,36). The isoquinolinone compounds are particularly interesting in that they lack the basic nitrogen center common in small molecule KOR ligands (10, [39] [40] [41] ; the bestknown ligand lacking this feature is salvinorin A, a natural neoclerdane diterpene found to be a highly selective, potent KOR agonist (19) .
Following their initial disclosure, these scaffolds were subjected to iterative rounds of medicinal chemistry and structure-activity relationship studies with the goal of developing KOR agonists that are biased towards G protein coupling. Here we report five triazole analogues and two isoquinolinone analogues ( Figure 1 ) that activate KOR in a manner that is preferentially biased towards G protein signaling with minimal effects on βarrestin2 recruitment and downstream ERK1/2 activation. Cell Lines and Cell Culture Chinese hamster ovary (CHO) cells expressing recombinant human kappa opioid receptor (CHO-hKOR cell line) were generated as described previously (42) . The CHO-hMOR cell line was a gift from Dr. Richard B. Rothman of NIDA, NIH (43). The CHOhDOR cell line was made by stably transfecting CHO cells with human DOR cDNA (Missouri S&T cDNA Resource Center, Rolla, MO). The CHO cell lines were maintained in DMEM/F-12 media (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 500 µg/ml geneticin (the parental CHO-K1 cell line was grown without geneticin). The by guest on September 1, 2017 http://www.jbc.org/ Downloaded from U2OS cell line stably expressing hKOR and βarrestin2-eGFP (U2OS-hKOR-βarrestin2-GFP) was a gift from Dr. Lawrence Barak, Duke University. These cells were maintained in MEM with 10% fetal bovine serum, 1% penicillin/streptomycin, 100 µg/ml geneticin and 50 µg/ml Zeocin. DiscoveRx PathHunter™ U2OS enzyme fragment complementation (EFC) cell line expressing βarrestin2 and hKOR (U2OS-hKORβarrestin2-EFC) or hMOR (U2OS-hMORβarrestin2-EFC) were purchased from DiscoveRx Corporation (Fremont, CA) and were maintained MEM with 10% fetal bovine serum, 1% penicillin/streptomycin, 500 µg/ml geneticin and 250 µg/ml hygromycin B. All cells were grown at 37°C (5% CO 2 and 95% relative humidity). Animals C57BL/6J male mice between 5-7 months old from The Jackson Laboratory (Bar Harbor, Maine) were used in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and with approval by The Scripps Research Institute Animal Care; the Scripps vivarium is fully AAALAC accredited.
EXPERIMENTAL PROCEDURES Compounds and Reagents
Membrane G Protein Signaling Membranes were prepared according to a modified procedure of Schmid et al. (2013) (42) . Briefly, CHO-hKOR cells were serum starved for 1 hour in DMEM/F-12 media, collected with 5 mM EDTA, washed with PBS, and stored at -80°C. For each assay, cell pellets were homogenized via Teflon-on-glass homogenizer in buffer (10 mM Tris-HCl pH 7.4, 100 mM NaCl, 1 mM EDTA), passed through a 26 gauge needle 8 times, centrifuged twice at 20,000 g for 30 minutes at 4°C, and resuspended in assay buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 5 mM MgCl 2 , 1 mM EDTA and 3 µM GDP). For each reaction, 15 µg of membrane protein were incubated in assay buffer containing ~ 0. Cellular Impedance CHO-hKOR cells were plated at 60,000 cells per well in CellKey™ microplates (Molecular Device, Sunnyvale, CA) in complete DMEM/F-12 media. The second day, the cells were equilibrated at room temperature in Hank's balanced salt solution (HBSS, Invitrogen) containing 0.1% BSA (fatty acid free, Sigma) and 20 mM HEPES for 30 minutes. Changes in impedance due to changes in extracellular current (Z iec ) were recorded using CellKey™ cellular analysis system (Molecular Device) for 35 minutes after treatment with increasing doses of compounds (45, 46) . Maximal changes in impedance were extracted and plotted in dose-response curves.
βArrestin2 Recruitment (EFC) The βarrestin2 EFC assays were performed according to the manufacturer's (DiscoveRx) protocol with slight modification as previously described (42 (42) . Single focal plane images were obtained using 100X objective between 5-20 minutes after drug treatment. Cells that did not respond to compound stimulation were treated with 10 µM U69,593 to validate the cell's potential to respond prior to concluding a negative drug effect (data not shown). Individual images were adjusted for brightness/contrast and size (scale bars are indicated).
Radioligand Binding Receptor binding assays were performed as previously described (42, 47 (42) . In brief, CHO-hKOR cells plated on 384-well plates, were treated with test compounds for 10 minutes, fixed with 4% paraformaldehyde, and permeabilized with 0.2% Triton X-100. After 1 hour incubation in blocking buffer (1:1, Li-Cor blocking buffer with PBS, containing 0.05% Tween-20) (LiCor), cells were then incubated with primary antibodies detecting phosphorylated ERK1/2 and total-ERK1/2 (Cell Signaling) at 4 °C overnight. After 4 washes with PBS + 0.1% Tween20 (PBS-T), and one with Li-Cor blocking buffer + 0.05% Tween20, cells were incubated with Li-Cor secondary antibodies (anti-rabbit IRDye800CW, 1:500; anti-mouse IRDye680LT, 1:1500) in Li-Cor blocking buffer containing 0.025% Tween-20 for 1 hour. Following an additional 4 washes with PBST, 1 wash with PBS, 1 wash with water, plates were dried and fluorescence signal was determined using the Odyssey Infrared Imager (Li-Cor Bioscience, Lincoln, NE) at 700 nm and 800 nm.
ERK1/2 Western Blot Analysis CHOhKOR cells in 6 well plates were serum starved for 1 hour prior to treatment (10 minutes) as previously described (42) . Antibodies to phosphorylated ERK1/2 and total ERK1/2 (Cell Signaling) were used and the ratio of phosphorylated ERK1/2 to total ERK1/2 were calculated and normalized to vehicle treatment. Percentage of response was calculated according to the maximal responses by 10 µM U69,593 stimulation.
Tissue (brain) distribution. Test compounds were formulated as 1 mg/ml solution in 10% DMSO, 10% Tween-80, and 80% dH 2 O and were dosed at 10 mg/kg intraperitoneally (i.p.) in C57Bl-6 mice. Brain and plasma samples were taken at 30 min and 60 min. Plasma and brain were mixed with acetonitrile (1:5 v:v or 1:5 w:v, respectively). The brain sample was disrupted with a probe tip sonicator. Samples were centrifuged at 16,000 x g and the compound concentration in the supernatant was determined using liquid chromatography (Shimadzu, Japan) /tandem mass spectrometry (AB Sciex, Franmingham, MA) operated in positive ion mode using multiple reaction monitoring methods. Separate standard curves were prepared in blank plasma and brain matrix. Brain concentration was calculated as compound per mg tissue and converted to a concentration assuming a density of 1 wherein 1 g of tissue equals 1 ml.
Pharmacokinetics. Pharmacokinetic parameters were determined in C57Bl-6 mice by intravenous (i.v.) dosing in the tail vein.
Mice (n=3) were dosed with drug at 2 mg/kg and approximately 20 µl blood was collected at 0, 5, 15, 30, 60, 120, 240, and 480 minutes post dose. Plasma was generated by standard centrifugation techniques resulting in approximately 10 µl of plasma which was immediately frozen. Drug levels were determined using an ABSciex 5500 mass spectrometer using multiple reaction monitoring and mass transitions of 431.3→ 81.1 for compound 1.1 and 461.3→286.1 for compound 2.1. Pharmacokinetic parameters were calculated using a non-compartmental model (Phoenix WinNonlin, Pharsight Inc.).
Plasma and brain binding. Plasma protein binding and non-specific brain binding were determined using equilibrium dialysis. All samples were tested in triplicate. A 96-well equilibrium dialysis chamber (HTDialysis, Gales Ferry, CT) with a 12,000 molecular weight cut off dialysis membranes were used. Human plasma and rat plasma were provided by a commercial vendor (PelFreez Biologicals, Rogers, AR). Equal volume of buffer and plasma containing 2.5 µM drug were added to opposite sides of the dialysis membrane. The plate was covered and allowed to shake in a 37°C incubator for 16 hours. Similar methods were used for nonspecific brain binding except a brain homogenate (1 part rat brain, 3 parts buffer) was used in place of the plasma. After 16 hours, the concentration of drug in the plasma/brain vs. plasma compartments was determined by LC-MS/MS. The fraction bound was calculated as
Determination of LogP. Estimation of octanol/water partition coefficient (LogP) was determined using a fast gradient reverse phase HPLC method as described by Valko et al. without modification (48) . Briefly, chromatographic retention times for test compounds and 10 standards were determined using a linear acetonitrile gradient on a Luna C18(2) 50 x 4.6 mm 5 mm column. Warm Water Tail-Immersion Antinociception was evaluated in the warm water tail-immersion (tail flick) assay (49 °C) as previously described (47, 49, 50) . In brief, the tip (~2 cm) of the mouse's tail was submerged in warm water and the time till it was withdrawn from the water was recorded. Response latencies were measured prior to (basal) and at indicated times following drug administration (30 mg/kg, i.p. given as 10 µL/g). U50,488H and the test compounds were prepared in a vehicle containing 10% Tween-80 and 10% DMSO in dH 2 O. A cutoff latency of 30 seconds was imposed to prevent tissue damage. Vehicle alone had no effect on response latencies (data not shown).
Data Analysis and Statistics Sigmoidal dose response curves were generated using three-parameter non-linear regression analysis in GraphPad Prism 6.01 software (GraphPad, La Jolla, CA). All compounds were run in parallel assays in 2-4 replicates per n.
The EC 50 values and maximal responses (E Max ) of drugs were obtained from the average of each individual experiment following nonlinear regression analyses and are reported as the mean ± standard error of the mean (S.E.M.).
In order to express the results of each response assay in a format suitable for comparison, each data set was fit, using GraphPad Prism v.6.01, to the operational model (51) expressed as the equation (52):
n where E Max is the maximal response of the system, A is the molar concentration of the drug, and K A is the equilibrium dissociation constant.
For each assay, the maximal response (E Max ) is constrained to be a shared value. The τ parameter is defined, in the operational model, as the agonist efficacy and the Log(τ/K A ) ratio (transduction coefficient) provides a single parameter value that is useful for the comparison of agonist activity (51) . For all studies, U69,593 is used as the reference compound and is assayed in parallel with the test compounds. In order to produce an appropriate estimate of Log(τ/K A ) for the full reference agonist (U69,593), in each assay, the LogK A for the full agonist was set constant at 0 (i.e. K A = 1M). The resulting Log(τ/K A ) ratio for the reference agonist is used to produce the "normalized" transduction coefficient (ΔLog(τ/K A ) ratio) for each of the test compounds:
For a limited number of test compounds in certain assays, the LogK A value in the equation was constrained to be less than 0 (i.e. K A <1 M) to permit convergence to the model. An asterisk in the tables indicates these few individual cases.
Bias factors (52) (53) (54) are calculated by subtracting the ΔLog(τ/K A ) test-U69 for each assay (ΔΔLog(τ/K A ) assay1-assay2 ) and are calculated as follows:
The statistical tests used are noted in the figure legends, wherein Student's t test indicates an unpaired, two-tailed analysis. All studies were performed n ≥ 3 independent experiments performed in multiple replicates.
RESULTS

KOR-mediated G protein signaling was evaluated using a [
35 S]GTPγS binding assay in cell membranes from CHO-K1 cells stably expressing the human KOR (CHOhKOR) (42) . Concentration response curves were run in parallel with U69,593, a well characterized potent, full agonist at KOR, as a reference agonist for the assay; EC 50 values and maximal responses of test compounds were determined by nonlinear regression analysis and are presented in Table 1 . Compared to U69,593 (51 nM potency), the triazole and isoquinolinone analogues show similar potencies for stimulating G protein signaling, with EC 50 values ranging from ~30 to 270 nM; with maximal stimulations roughly equivalent to that achieved with U69,593 stimulation ( Figure 2 ; Table 1 ). Furthermore, none of these compounds stimulate G protein signaling in CHO cells expressing hMOR when tested at a 10 µM concentration (data not shown) demonstrating selectivity for KOR.
To determine the relative potencies for recruiting βarrestin2 to the agonist-stimulated KOR, two cell-based assays, as described in the MLPCN probe report were used (35). The commercial EFC assay consists of U2OS cells expressing human KOR and βarrestin2 (U2OS-hKOR-βarrestin2-EFC), each tagged with a fragment of β-galactosidase. The degree of βarrestin2 recruitment is measured as increases in luminescence intensities triggered by enzyme complementation occurring upon receptor and βarrestin2 engagement (55) . The second assay utilizes U2OS cells expressing human KOR and βarrestin2 tagged with green fluorescent protein (U2OS-hKOR-βarrestin2-GFP) (56, 57) . The translocation of βarrestin2-GFP is measured by automated high content imaging analysis that detects a difference in diffuse cellular GFP distribution to the agonist-induced formation of fluorescent punctae (56) . In both cases, U69,593 is used as the full agonist, reference ligand.
While maintaining potent agonism in the G protein signaling assays, the triazole and isoquinolinone compounds only weakly recruit βarrestin2, with potencies exceeding 2 µM in both assays, while the potency of U69,593 is ~130 nM in the βarrestin2 EFC assay and ~205 nM in the imaging assay ( Figure 3 ; Table 1 ). Examination of the concentration response curves in both assay platforms ( Figure 3A , C) reveals that each of the triazole compounds shows minimal βarrestin2 recruitment at lower concentrations (< 1 µM). However, stimulation dramatically increases at higher concentrations (> 1 µM); this is also true for compound 2.1 of the isoquinolinones (Figure 3B, D) . This phenomenon was verified for representative compounds using confocal microscopy to visualize βarrestin2-GFP translocation in the U2OS cells (not shown) that confirmed the results obtained in the high content imaging platform ( Figure 3C & D) .
G protein signaling and βarrestin2 recruitment were, by design, performed in different cellular backgrounds (CHO-hKOR and U2OS-hKOR-βarrestin2-EFC or U2OS-hKOR-βarrestin2-GFP). The U2OS cell line was used for the commercial enzyme fragment complementation assay because it gave a larger assay window than that observed for the CHO-hKOR-βarrestin2-EFC commercial assay that is also available from the manufacturer. This was preferred in order to bias the system towards detecting even weak 9 βarrestin2-KOR interactions. Furthermore, even though CHO-hKOR-βarrestin2-EFC cells could be used, it is important to realize that the KOR and βarrestin2 are linked to fragments of β-galactosidase and therefore, although the parental cell line is of the same origin, the stably transfected cell lines are not identical.
In order to determine if the cell line (U2OS vs. CHO-K1) contributed to the apparent bias, we also evaluated βarrestin2 (tagged with YFP) recruitment in the CHOhKOR cell line by confocal microscopy for select agonists of each class. In the confocal microscopy studies of CHO-hKOR cells, 1.1 does not promote βarrestin2 recruitment at low concentrations (100 nM and 1 µM), but induces punctae formation at 10 µM ( Figure  3E) , consistent with the studies in U2OS cell imaging assays and the EFC βarrestin2 assay. The ability to visualize the agonist-induced βarrestin2 recruitment also suggests that the positive signal at high concentrations is not an artifact of the assay. In contrast to the observations in the other βarrestin2 assay platforms, 2.1 revealed no visible recruitment of βarrestin2-YFP even at 10 µM, in the CHO-hKOR cells ( Figure 3E ). The lack of response to 2.1 in the CHO-hKOR cells transfected with βarrestin2-YFP is likely due to a low detection window with the low degree of stimulation falling below detectable thresholds. Finally, when tested in the MOR EFC assay, no stimulation is seen at any dose (1, 10, and 100 µM), which also argues against the effect being an artifact of the assay (data not shown).
The studies presented in Tables 1 and  in Figures 2 & 3 suggest that the triazole and isoquinolinone analogues presented here bias KOR function toward G protein signaling over the recruitment of βarrestin2. In order to compare the relative differences within and between assays, curves were fit to the operational model (51) to derive transduction coefficients (Log(τ/K A )) for the reference ligand (U69,593) and the "test" ligands using GraphPad Prism v.6.01, as described previous (42, 52, 54) .
The transduction coefficient represents the relative propensity of the ligand to generate a signal proportional to the agonist's calculated relative affinity for engaging the receptor based on its performance in the assay.
Subtracting the Log(τ/K A ) for U69,593 from the values obtained for the "test" ligands generates a "normalized" transduction coefficient for the test ligand within the assay, or the ΔLog(τ/K A ).
To determine preference between assays, bias factors were calculated as described in the methods (Table 2 ( 54)). Although such modeling may be imperfect for extreme cases of bias, we have presented the analysis here for qualitative comparison; each of the compounds displays bias for activation of KOR towards G protein signaling over βarrestin2 recruitment.
Since the [ 35 S]GTPγS binding assay was performed in membrane preparations while the βarrestin2 recruitment studies were performed in whole cells, we considered that these contextual differences could confound our interpretations of bias. Therefore, we selected a representative triazole and isoquinolinone and performed two additional G protein signaling assays in whole cell preparations (Figure 4) .
Using a low concentration of saponin to permeabilize the CHO-hKOR cells allowing uptake of the radionucleotide, [
35 S]GTPγS binding was performed in whole cells plated on 96-well plates ( Figure 4A ). U69,593, 1.1 and 2.1 potently stimulate G protein signaling in this whole cell assay. Furthermore, in the absence of the brief permeabilization step, U69,593 does not induce [
35 S]GTPγS binding due to the lack of available radionucleotide inside the cell.
A label-free, cellular impedance assay was also utilized to assess relative potencies in the living CHO-hKOR cells ( Figure 4B ). This assay measures changes in impedance resulting from cytoskeletal re-organization leading to changes in cell shape (45) . GPCRs promote actin reassembly patterns reflective of the coupling of particular Gα proteins. In our analysis, the cellular response signature resembles that of a typical G αi -coupled GPCR ( Figure 4C ) (58) . Importantly, no response was observed in the parental CHO cell line (data not shown). In this live cell assay format, 1.1 and 2.1 are fully efficacious and nearly as potent as U69,593 in promoting KOR-dependent responses indicative of G protein signaling (Table 3) .
Further analysis was undertaken to compare all G protein signaling assays to all βarrestin2 recruitment assays. Data from Tables 2 & 3 were used to determine bias factors which are presented graphically in Figure 5 . In summary, regardless of the assay format and the cell type, the triazole and isoquinolinone maintain bias towards KORinduced G protein signaling over βarrestin2 recruitment.
In order to further characterize the compounds at a downstream signaling pathway, ERK1/2 phosphorylation was investigated. GPCRs can utilize both G protein-dependent and βarrestin-mediated signaling pathways to activate ERK1/2 map kinases (34). Interestingly, both classes of compounds activate ERK with potencies between 300 -6000 nM as compared to ~5 nM for U69,593. While this appears to correlate with their relative potency for recruiting βarrestin2 ( Figure 6A ,B, Table 4 ) further experiments must be undertaken to further define these pathways.
Of additional note, is that while these agonists are not very potent in this assay, their efficacy for activating ERK exceeds that of the reference compound, U69,593. Since the assay utilized here involves an immunohistochemistry approach, it is possible that the increase in fluorescence could be due to the induction of other kinases that may be recognized by the phospho-specific ERK1/2 antibodies used. Therefore, western blot analysis was performed to determine if the increase in phosphorylation detected could be attributed to the 42 and 44 kDa bands, p-ERK1 and p-ERK2, respectively. Western blot analysis confirmed that the intensity of 42 and 44 kDa bands are elevated over that observed for U69,593-induced phosphorylation suggesting that this effect is not an artifact of the 384-well plate immunohistochemistry approach ( Figure 6C) . Furthermore, none of the compounds activate ERK1/2 in the CHO-K1 parental cell line when tested at 1, 10 or 20 µM suggesting that these effects are KOR-dependent (data not shown).
Since the efficacy of the test compounds exceeded that of the reference compound in this assay, U69,593 was insufficient to define the maximum potential of the system and therefore, these data were not fit to the operational model. Additional studies, investigating differences in ERK1/2 populations (cytosol and nuclear) as well as the temporal regulation of ERK1/2 phosphorylation will be needed to make accurate comparisons between the agonists.
It is possible that, given the different receptor expression levels and cellular context, the ligands may not have comparable opportunities to interact with the receptor. Ultimately, these compounds, of which there is a growing collection, may become important tools for ascertaining the relative contributions of G protein-dependent, βarrestin2-independent signaling at KOR in vivo. As an early step in characterization, the pharmacokinetic properties of 1.1 and 2.1 were assessed in mice. Brain and plasma compound content were determined following a single systemic, intraperitoneal (i.p.) administration (10 mg/kg, i.p.) wherein both compounds were detected at low micromolar concentrations in brain at 30 and 60 minutes (Table 6 ). Pharmacokinetic distribution and clearance rates were determined following a 2 mg/kg (i.v.) tail vein injection and timed blood collections. Plasma protein binding and nonspecific brain binding were also determined for these compounds. These parameters, along with the determined "LogP" values are presented in Table 7 and indicate good brain exposure, and reasonable pharmacokinetic properties. Together these findings suggest that these scaffolds may represent favorable leads for development of biased KOR agonists with CNS penetration.
Since G protein-mediated KOR signaling has been proposed as the mechanism underlying KOR-mediated antinociception, the antinociceptive effects of 1.1 and 2.1 were then assessed using the warm water tail-flick assay (Figure 6 (10,59 ). Mice were injected with 30 mg/kg, i.p. doses of either 1.1, 2.1 or the selective KOR agonist U50,488H, as this dose of U50,488H has been shown to induce antinociception in mice in this assay (60) . The triazole and isoquinolinone compounds significantly increased the latency to tail withdrawal similar to that seen with U50,488H, with the effects peaking at 20 minutes post drug treatment (Figure 7 ) demonstrating that these agonists are capable of inducing antinociception in mice.
DISCUSSION
The triazole and isoquinolinone analogues described herein are highly selective KOR agonists that induce receptor signaling biased toward G protein signaling over βarrestin2 recruitment. When tested in vivo, 1.1 and 2.1, a triazole and an isoquinolinone respectively, prove to be brain penetrant. Subsequently, 1.1 and 2.1 produce antinociception in the mouse tail flick test, which correlates with the ability of these compounds to potently activate G protein signaling in cell-based assays.
Prior studies suggest that KOR agonists that do not engage βarrestin2-mediated signaling pathways may prove to have less aversive properties such as dysphoria (30, 61, 62) (Figure 8 ). It is hopeful that the generation of compounds such as those in the series described here, will provide pharmacological tools that will aid in the elucidation of KOR-mediated signaling cascades in cellular systems, and importantly, in vivo. The fact that these series possess very high affinity and selectivity for KOR over other opioid receptors, are brain penetrant and have favorable pharmacokinetic parameters, will certainly aid in these ventures.
Recently, Rives et al. found the naltrindole-derived ligand 6'-GNTI to be a potent partial agonist for KOR-stimulated G protein signaling yet an antagonist for recruiting βarrestins (62) . From our laboratory, Schmid et al. recently confirmed the delineation of this bias in vitro and further explored it in cultured striatal neurons (42) . Although 6'-GNTI potently activates ERK1/2 in CHO-hKOR cells, in neurons, 6'-GNTI does not activate ERK1/2 while U69,593 does so in a βarrestin2-dependent manner, suggesting that KOR utilizes βarrestin2 to activate ERK in the endogenous setting (42) . The triazole and isoquinolinone compounds investigated herein differ from 6'-GNTI in that they are full agonists in G protein signaling and they are able to activate βarrestin2 recruitment in the cell based assays, although at a greatly diminished potency. Furthermore, the triazoles and isoquinolinones do not potently activate ERK1/2, further distinguishing them from 6'-GNTI. The increasing number of compounds identified with diverse signaling profiles downstream of KOR activation may be useful for docking studies to the continually refined crystal structure of these GPCRs (63) which may provide insight into the chemical signatures driving specific receptor confirmations and signaling events.
The triazoles and isoquinolinones consistently activated ERK1/2 with less potency than that observed for U69,593. Therefore, it is attractive to speculate that the triazoles and isoquinolinones are biased toward G protein signaling over ERK1/2 phosphorylation. We hesitate, however, to make this claim based on two confounds. First, the ERK activation profile of most of the agonists surpasses the maximal effect elicited by the reference compound. Therefore, for this particular pathway, U69,593 does not adequately serve as a reference compound. The second confound, and perhaps the most important, is that ERK1/2 activation is a downstream effector that represents the consolidation of multiple upstream cascades (potentially originating from affecting different G proteins, βarrestins, calcium influx, etc.). While our negative controls demonstrate that the activation of ERK by the test compounds is due to KOR (no response in parental CHO-K1 cells), it is difficult to interpret what component of cellular signaling is participating more (overshoot in efficacy) or less (rightward shift in potency) in generating the response profile elicited by these compounds downstream of KOR. Regardless, the compounds consistently reveal more potency in the G protein signaling assay than in the ERK1/2 and βarrestin assays. Overall, these results are intriguing and represent an area for further explorations into the compartmental (nuclear vs. cytoplasmic (64)) and temporal (transient or sustained (28,64)) aspects of GPCR-stimulated ERK activation in respect to βarrestin and G proteindependent mechanisms.
It will be of great interest to utilize these compounds in additional behavioral and physiological assays to determine the contribution of βarrestin2 to KOR signaling in vivo. However, it will first be important to determine that the signaling bias observed across the various cell-based assay platforms is maintained in vivo and whether these pathways are associated with behaviors. If indeed these newly discovered KOR biased agonists, which are brain penetrant following systemic injections, prove to maintain signaling bias in the endogenous setting, these compounds may serve as important tools for investigating the contributions of ERK activation and/or βarrestin2-recruitment to KOR-mediated effects in vivo and it is hopeful that these new pharmacological tools will serve the community for exploring relevant KOR biology in an endogenous setting.
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35 S]GTPγS binding; ~8 fold for the EFC assay and ~20 fold for the imaging assay. EC 50 and E MAX values we calculated as described in Table 1 . Bias Factors (ΔΔLog(τ/K A ) assay1-assay2 ) were calculated as described in the methods. βarrestin2 EFC and βarrestin2 Imaging transduction coefficients are found in Table 2 . The notation "*", indicates LogK A values were constrained to < 0 (less than 1M relative affinity) to permit convergence to the operational model. n ≥ 5 individual assays; means are presented ± S.E.M. Maximal stimulation over vehicle treatment with U69,593 was ~2 fold for whole cell [ 35 S]GTPγS binding (wcG) and ~8 fold for the cellular impedance assay (Imped). E MAX values are calculated based on U69,593 maximal stimulation. n ≥ 3 individual assays; means are presented ± S.E.M. Maximal stimulation over vehicle treatment with U69,593 was ~4 fold. ?
